NCT03246542

Brief Summary

HELLP syndrome is a life-threatening obstetric complication usually considered to be a variant or complication of pre-eclampsia. And may occasionally be confused with other diseases complicating pregnancy such as acute fatty liver of pregnancy, gastroenteritis, hepatitis, appendicitis, gallbladder disease, immune thrombocytopenia, lupus flare, antiphospholipid syndrome, hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura, and nonalcoholic fatty liver disease. The distinction between thrombotic thrombocytopenic purpura-hemolytic uremic syndrome and severe preeclampsia is important for therapeutic and prognostic reasons. However, the clinical and histological features are so similar that establishing the correct diagnosis is often difficult; furthermore, these disorders may occur concurrently.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2015

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2015

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2016

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

July 23, 2017

Completed
19 days until next milestone

First Posted

Study publicly available on registry

August 11, 2017

Completed
Last Updated

August 11, 2017

Status Verified

August 1, 2017

Enrollment Period

11 months

First QC Date

July 23, 2017

Last Update Submit

August 9, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • laboratory changes after 48 hours of delivery

    full blood count, liver function tests( AST, ALT, Bilirubin), kidney function (serum creatinine level), coagulation profile (INR, PTT, PT)

    48 hours

Interventions

shistocytes percentageDIAGNOSTIC_TEST

Eligibility Criteria

Age20 Years - 40 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

A total of 100 women with an initial diagnosis of HELLP syndrome were recruited in the study. Blood sample taken within 12hrs peripartum and patients followed up 48hrs after delivery and subdivided in to 2 groups according to improvement or deterioration after 48hrs after delivery .

You may qualify if:

  • Gestational age more than 20 weeks.
  • Age from18 to 40 years old.
  • Fulfilled criteria for the diagnosis of severe preeclampsia.
  • Fulfilled criteria for the diagnosis of HELLP syndrome.
  • Diagnostic criteria for severe preeclampsia(one of the following):
  • Blood pressure of 160 mm Hg systolic or higher or 110 mm Hg diastolic or higher on two occasions at least 6 hours apart while the patient is on bed rest (unless antihypertensive therapy is intiated befor this time).
  • New onest Cerebral or visual disturbances.
  • Pulmonary edema or cyanosis.
  • Sever persistant epigastric or right upper-quadrant pain unresponsive to medication and not accounted for by alternative diagnosis, or both.
  • Impaired liver function as indicated by abnormally elevated blood concentration of liver enzymes (to twic normal concentration).
  • Thrombocytopenia (platlet count less than 100, 000 per microliter.
  • Diagnostic criteria for HELLP syndrome:
  • Hemolysis documented by an increased LDH level and progressive anemia .
  • Hepatic dysfunction documented by an LDH level \>600 IU/L, elevated liver enzymes documented by AST \>40 IU/L, ALT\>40 IU/L, or both .
  • Thrombocytopenia documented by a platelet nadir less than 150, 000 cells/mm³. Thrombocytopenia is subclassified as class one HELLP syndrome: platelet nadir ≤50, 000 cells/mm³, class two HELLP syndrome: platelet nadir ≤100, 000 cells/mm³, or class three HELLP syndrome: platelet nadir ≤150, 000 cells/mm³..
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Pre-EclampsiaHELLP Syndrome

Condition Hierarchy (Ancestors)

Hypertension, Pregnancy-InducedPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
2 Days
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
doctor

Study Record Dates

First Submitted

July 23, 2017

First Posted

August 11, 2017

Study Start

January 1, 2015

Primary Completion

December 1, 2015

Study Completion

June 1, 2016

Last Updated

August 11, 2017

Record last verified: 2017-08

Data Sharing

IPD Sharing
Will not share